Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Epithelial Cancers of the Lung, Breast, Ovary, Prostate and Colon
Interventions: DRUG: Ad-sig-hMUC-1/ecdCD40L vector vaccine
Sponsor: Singapore Clinical Research Institute
Collaborators: MicroVAX, LLC|ClinDatrix, Inc.